UI Hospitals and Clinics

Clinical Trial Details

Short Title
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults with Brain Tumors
Official Title

Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults with Brain Tumors

Description

Participants in this research study have been diagnosed with a brain tumor that has cells with special proteins called somatostatin receptors.

The purpose of this research study is to see if participants' tumors can be identified using a special procedure called a positron emission tomography (PET) scan. They will have an injection with a radioactive drug called 68Gallium-DOTA-tyr3-Octreotide (68Ga-DOTATOC) that binds to tumor cells that have somatostatin receptors and then have a PET scan. Participants will then have a "low dose" computed tomography (CT) scan immediately after the PET scan on the same scanner. 68Ga-DOTATOC is considered investigational, which means that it has not yet been approved by the U.S. Food and Drug Administration (FDA). The FDA has granted permission to conduct this study under an investigator's new drug (IND) application.

About 30 people will take part in this study conducted by investigators at the University of Iowa.

Start Date
September 11, 2013
End Date
June 30, 2014
Gender Preference
None
Age Group
0 - 29 years
Principal Investigator
Chenue Abongwa, MD
Contact Info

Chenue Abongwa, 319-356-4328

Department
Hematology/Oncology
Keywords
201302711 ; abongwa ; brain tumor ; cancer ; imaging ; pediatric ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.